JPMorgan Healthcare Leaders ETF
JPMorgan Healthcare Leaders ETF reported 71 holdings worth US$9.07M as of Jul 31, 2026 (Form N-PORT)
As of Jul 31, 2026 · Filed Sep 28, 2026
JPMorgan Healthcare Leaders ETF reported 71 holdings worth US$9.07M as of Jul 31, 2026. Largest: Abbvie Inc., Eli Lilly And Company and Unitedhealth Group Incorporated. Filed Sep 28, 2026 (Form N-PORT).
- Holdings
- 71
- Value as reported
- US$9.07M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Abbvie Inc. | 2,838 | US$712K | 7.8% |
| Eli Lilly And Company | 613 | US$704K | 7.8% |
| Unitedhealth Group Incorporated | 1,281 | US$531K | 5.8% |
| Merck & Company, Inc. | 3,359 | US$437K | 4.8% |
| Johnson & Johnson | 1,706 | US$437K | 4.8% |
| Astrazeneca Plc | 2,007 | US$341K | 3.8% |
| Thermo Fisher Scientific Inc | 590 | US$339K | 3.7% |
| Bristol-myers Squibb Company | 4,962 | US$324K | 3.6% |
| Abbott Laboratories | 2,669 | US$282K | 3.1% |
| Cvs Health Corporation | 2,458 | US$257K | 2.8% |
| Roche Holding Ltd | 586 | US$256K | 2.8% |
| Novo Nordisk A/s Class B | 5,014 | US$237K | 2.6% |
| Gsk Plc | 8,605 | US$224K | 2.5% |
| Argenx Se | 231 | US$214K | 2.4% |
| Stryker Corporation | 620 | US$202K | 2.2% |
| Danaher Corporation | 1,006 | US$196K | 2.2% |
| Cencora, Inc. | 604 | US$188K | 2.1% |
| Intuitive Surgical, Inc. | 496 | US$175K | 1.9% |
| Edwards Lifesciences Corporation | 1,827 | US$157K | 1.7% |
| Iqvia Holdings, Inc. | 661 | US$155K | 1.7% |
| Teva Pharmaceutical Industries Limited | 4,279 | US$145K | 1.6% |
| Regeneron Pharmaceuticals, Inc. | 190 | US$145K | 1.6% |
| Novartis Ag | 926 | US$145K | 1.6% |
| Biogen Inc. | 699 | US$142K | 1.6% |
| Cardinal Health, Inc. | 597 | US$137K | 1.5% |
| Takeda Pharmaceutical Co. Ltd. | 3,400 | US$117K | 1.3% |
| Centene Corporation | 1,740 | US$108K | 1.2% |
| Hoya Corporation | 700 | US$107K | 1.2% |
| Humana Inc. | 290 | US$106K | 1.2% |
| Boston Scientific Corporation | 2,069 | US$96,684 | 1.1% |
| Fresenius Se & Co. Kgaa | 1,831 | US$94,108 | 1.0% |
| Insmed Incorporated | 894 | US$88,148 | 0.97% |
| Genmab A/s | 263 | US$75,702 | 0.83% |
| Sartorius Ag | 298 | US$75,106 | 0.83% |
| Dyne Therapeutics, Inc. | 2,968 | US$74,734 | 0.82% |
| Vertex Pharmaceuticals Incorporated | 155 | US$73,951 | 0.81% |
| Spyre Therapeutics, Inc. | 710 | US$69,814 | 0.77% |
| Neurocrine Biosciences, Inc. | 399 | US$66,553 | 0.73% |
| Bridgebio Pharma, Inc. | 822 | US$65,834 | 0.73% |
| Alnylam Pharmaceuticals, Inc. | 311 | US$63,917 | 0.70% |
| Align Technology, Inc. | 376 | US$63,604 | 0.70% |
| Charles River Laboratories International, Inc. | 259 | US$60,220 | 0.66% |
| Cg Oncology, Inc. | 791 | US$56,311 | 0.62% |
| Ascendis Pharma A/s | 218 | US$53,172 | 0.59% |
| Alumis Inc. | 1,834 | US$51,811 | 0.57% |
| Lb Pharmaceuticals Inc | 1,258 | US$50,421 | 0.56% |
| Disc Medicine, Inc. | 600 | US$46,200 | 0.51% |
| Ptc Therapeutics, Inc. | 658 | US$44,751 | 0.49% |
| Bicara Therapeutics Inc. | 1,484 | US$40,216 | 0.44% |
| Arcus Biosciences, Inc. | 1,384 | US$39,015 | 0.43% |
| Erasca, Inc. | 1,956 | US$35,501 | 0.39% |
| Medtronic Plc. | 367 | US$31,338 | 0.35% |
| Sionna Therapeutics, Inc. | 21 | US$990 | 0.01% |
| Evommune, Inc. | 0 | US$0 | 0.00% |
| Ucb S.a. | 0 | US$0 | 0.00% |
| Daiichi Sankyo Company, Limited | 0 | US$0 | 0.00% |
| Convatec Group Plc | 0 | US$0 | 0.00% |
| Xenon Pharmaceuticals Inc. | 0 | US$0 | 0.00% |
| Hca Healthcare, Inc. | 0 | US$0 | 0.00% |
| Lonza Group Ag | 0 | US$0 | 0.00% |
| Zoetis Inc. | 0 | US$0 | 0.00% |
| Viridian Therapeutics, Inc. | 0 | US$0 | 0.00% |
| United Therapeutics Corporation | 0 | US$0 | 0.00% |
| Immunome, Inc. | 0 | US$0 | 0.00% |
| The Cigna Group | 0 | US$0 | 0.00% |
| Bio-techne Corp | 0 | US$0 | 0.00% |
| Apogee Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Nuvalent, Inc. | 0 | US$0 | 0.00% |
| Dexcom, Inc. | 0 | US$0 | 0.00% |
| Mckesson Corporation | 0 | US$0 | 0.00% |
| Ionis Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
Source
View original at SEC
Related